Q-omics provides the consensus-scored SCRN1 profile across patient tissues and cancer cell-line models. SCRN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SCRN1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SCRN1 protein abundance shows 22,786 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, HNSC, and PDAC as cancer lineages where SCRN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCRN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCRN1 survival associations across molecular data types. SCRN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCRN1 RNA expression–survival associations across cancer types. High SCRN1 expression shows unfavorable associations in BLCA, BRCA, UCEC, ACC, LIHC and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for SCRN1 RNA expression.
This table summarizes SCRN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SCRN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCRN1 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUAD, KIRP, LUSC and CHOL. The HNSC box plot shows higher SCRN1 RNA expression in tumor versus normal tissue (log2 FC = +1.872, t-test p < 0.001).
This table shows molecular features associated with SCRN1 in patient tissues and cancer cell lines. In patient samples, SCRN1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SCRN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
